Abstract
We created a cost-benefit analysis and swift point-of-care (PoC) testing for early stage Parkinson's disease (PD) that delivers the possibility of providing sensitive, rapid, and user-friendly analysis in home diagnostics applications. α-Synuclein (α-Syn) is considered a meaningful biomarker for the diagnosis of early stage PD. The PoC platform for diagnosis of PD is simply constructed with a conductive polymer and an aptamer receptor on a screen-printed electrode and exhibits a remarkable low detection limit of 1 × 10-3 fM. The developed PoC platform will offer an opportunity for individuals to conveniently and periodically check the progress of the diseases and success through expansion as a checkup platform for other diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
